CN116077548A - 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法 - Google Patents

用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法 Download PDF

Info

Publication number
CN116077548A
CN116077548A CN202211672521.2A CN202211672521A CN116077548A CN 116077548 A CN116077548 A CN 116077548A CN 202211672521 A CN202211672521 A CN 202211672521A CN 116077548 A CN116077548 A CN 116077548A
Authority
CN
China
Prior art keywords
composition
weight
acid
cranberry
quercetin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211672521.2A
Other languages
English (en)
Chinese (zh)
Inventor
E·A·C·弗洛芒坦
D·A·克莱贝
D·D·苏扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN116077548(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of CN116077548A publication Critical patent/CN116077548A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202211672521.2A 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法 Pending CN116077548A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
US61/902,376 2013-11-11
CN201480070244.5A CN105848663A (zh) 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480070244.5A Division CN105848663A (zh) 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法

Publications (1)

Publication Number Publication Date
CN116077548A true CN116077548A (zh) 2023-05-09

Family

ID=53042226

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211672521.2A Pending CN116077548A (zh) 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法
CN201480070244.5A Pending CN105848663A (zh) 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480070244.5A Pending CN105848663A (zh) 2013-11-11 2014-11-11 用于治疗下泌尿道症状、良性前列腺肥大、勃起功能障碍的组合物和方法

Country Status (21)

Country Link
US (5) US20160324911A1 (https=)
EP (2) EP3068414B1 (https=)
JP (2) JP6966196B2 (https=)
KR (2) KR102745710B1 (https=)
CN (2) CN116077548A (https=)
AU (1) AU2014346415B2 (https=)
BR (1) BR112016010509B1 (https=)
CA (2) CA2928631C (https=)
CL (1) CL2016001109A1 (https=)
CR (1) CR20160254A (https=)
ES (2) ES2980381T3 (https=)
IL (1) IL245552B (https=)
MX (1) MX373448B (https=)
MY (1) MY184225A (https=)
NZ (1) NZ719268A (https=)
PH (1) PH12016500780A1 (https=)
PL (1) PL3068414T3 (https=)
RU (1) RU2696584C1 (https=)
SG (2) SG11201603462SA (https=)
WO (1) WO2015070203A1 (https=)
ZA (1) ZA201602941B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201603462SA (en) * 2013-11-11 2016-05-30 Naturex Dbs Llc Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
WO2018134962A1 (ja) * 2017-01-20 2018-07-26 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
US20200360466A1 (en) * 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US20220400727A1 (en) * 2019-11-08 2022-12-22 Cj Cheiljedang Corporation Composition containing polyphenol
EP4205756A4 (en) * 2020-08-31 2024-10-23 K-Biotech Co., Ltd. PHARMACEUTICAL COMPOSITION COMPRISING AN EXTRACT OF ABELIOPHYLLUM DISTICHUM AS ACTIVE INGREDIENT FOR TREATING AN ANDROGEN RECEPTOR-RELATED DISEASE
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물
WO2025038998A1 (en) * 2023-08-17 2025-02-20 University Of Wyoming Materials and methods for inhibiting, preventing, and dispersing biofilms
WO2025078239A1 (en) 2023-10-09 2025-04-17 Givaudan Sa Compositions
CN120204245A (zh) * 2024-12-12 2025-06-27 湖北医药学院 连翘苷在制备预防或治疗高尿酸血症的药物中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010012525A1 (en) * 1998-04-30 2001-08-09 Mann Douglas L. Infused vegetable, herb, and/or seed fiber product and dietary supplements containing same
US20060088610A1 (en) * 2003-11-10 2006-04-27 Nicholi Vorsa Anti-inflammatory cranberry flavonol extract preparations
CN101084944A (zh) * 2006-06-08 2007-12-12 林志雄 预防或治疗泌尿系统感染的组合物
CN101095764A (zh) * 2007-07-13 2008-01-02 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
CN101784279A (zh) * 2007-06-27 2010-07-21 科洛普拉斯特公司 使用皂角苷和抗生素的混合物治疗泌尿道感染
CN101999648A (zh) * 2010-10-11 2011-04-06 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
CN102149382A (zh) * 2008-08-19 2011-08-10 赛诺菲-安万特 屈他维林的新治疗用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
AU2005201455A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
JP2008500027A (ja) * 2004-05-03 2008-01-10 ノーザン ライツ フード プロセシング，エルエルシー ベリーオイルおよび製品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
WO2011088420A1 (en) 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
US20130122146A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food
SG11201603462SA (en) * 2013-11-11 2016-05-30 Naturex Dbs Llc Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010012525A1 (en) * 1998-04-30 2001-08-09 Mann Douglas L. Infused vegetable, herb, and/or seed fiber product and dietary supplements containing same
US20060088610A1 (en) * 2003-11-10 2006-04-27 Nicholi Vorsa Anti-inflammatory cranberry flavonol extract preparations
CN101084944A (zh) * 2006-06-08 2007-12-12 林志雄 预防或治疗泌尿系统感染的组合物
CN101784279A (zh) * 2007-06-27 2010-07-21 科洛普拉斯特公司 使用皂角苷和抗生素的混合物治疗泌尿道感染
CN101095764A (zh) * 2007-07-13 2008-01-02 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
CN102149382A (zh) * 2008-08-19 2011-08-10 赛诺菲-安万特 屈他维林的新治疗用途
CN101999648A (zh) * 2010-10-11 2011-04-06 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALES VIDLAR;等: "The effectiveness of dried cranberries (Vaccinium macrocarpon) in men with lower urinary tract symptoms", BRITISH JOURNAL OF NUTRITION, vol. 104, pages 1181, XP055585978, DOI: 10.1017/S0007114510002059 *
E. PAPPAS;等: "Phytochemicals of Cranberries and Cranberry Products: Characterization, Potential Health Effects, and Processing Stability", CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, vol. 49, pages 1 - 3 *
尹喜玲;等: "预防泌尿道感染的天然食品――蔓越莓", 中国食物与营养, no. 02, pages 49 *
温志强;等: "下尿路症状相关疾病的临床特点分析", 广东医学, vol. 34, no. 10, pages 1556 *

Also Published As

Publication number Publication date
MX373448B (es) 2020-06-11
PL3068414T3 (pl) 2021-08-30
US11291703B2 (en) 2022-04-05
WO2015070203A9 (en) 2016-01-14
SG10201910781SA (en) 2020-01-30
US20160324911A1 (en) 2016-11-10
US20190358282A1 (en) 2019-11-28
JP6966196B2 (ja) 2021-11-10
IL245552B (en) 2020-07-30
CL2016001109A1 (es) 2016-12-02
ZA201602941B (en) 2022-05-25
CA2928631A1 (en) 2015-05-14
US10898534B2 (en) 2021-01-26
US11045511B2 (en) 2021-06-29
IL245552A0 (en) 2016-06-30
KR20230004886A (ko) 2023-01-06
ES2980381T3 (es) 2024-10-01
WO2015070203A1 (en) 2015-05-14
US20200121750A1 (en) 2020-04-23
EP3068414A4 (en) 2017-06-07
ES2860773T3 (es) 2021-10-05
PH12016500780B1 (en) 2016-06-13
EP3068414A1 (en) 2016-09-21
CA2928631C (en) 2025-08-12
CN105848663A (zh) 2016-08-10
NZ719268A (en) 2021-07-30
US20180256663A1 (en) 2018-09-13
KR102476969B1 (ko) 2022-12-12
US12233101B2 (en) 2025-02-25
EP3782634A1 (en) 2021-02-24
AU2014346415B2 (en) 2020-04-23
JP2016539183A (ja) 2016-12-15
BR112016010509A2 (pt) 2017-08-08
AU2014346415A1 (en) 2016-05-12
JP2020059725A (ja) 2020-04-16
RU2696584C1 (ru) 2019-08-05
EP3782634B1 (en) 2024-03-20
PH12016500780A1 (en) 2016-06-13
CA3277615A1 (en) 2025-10-30
MY184225A (en) 2021-03-28
KR102745710B1 (ko) 2024-12-20
SG11201603462SA (en) 2016-05-30
US20220175863A1 (en) 2022-06-09
BR112016010509B1 (pt) 2021-08-17
KR20160079884A (ko) 2016-07-06
RU2016122062A (ru) 2017-12-19
EP3068414B1 (en) 2020-12-30
CR20160254A (es) 2016-08-31
JP7083330B2 (ja) 2022-06-10
MX2016005810A (es) 2016-11-18

Similar Documents

Publication Publication Date Title
JP7083330B2 (ja) 下部尿路症状、良性前立腺過形成、勃起障害の治療に有用な組成物及び方法
Karuppagounder et al. Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFκB p65 mediated inflammation
JP6310971B2 (ja) Ｈｉｖ関連の下痢を治療するための方法および組成物
Kumaran et al. Evaluation of an Ayurvedic formulation (Cystone), in urolithiasis: A double blind, placebo-controlled study
AU2018278312B2 (en) Methods and compositions for treating congenital diarrhea disorder
US12458678B2 (en) Composition for preventing or treating prostatic hyperplasia comprising mixed extracts of Curcumae radix and Syzygii flos
CN105944104B (zh) 一种治疗消化道溃疡的药物组合物
HK1228782A1 (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
HK1228782B (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
WO2015092123A1 (en) Compositions comprising glycerophosphorylethanolamine
CN104394874A (zh) 用于治疗动脉硬化性血管病的方法和组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination